205 related articles for article (PubMed ID: 10477454)
1. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
Rupoli S; Barulli S; Guiducci B; Offidani M; Mozzicafreddo G; Simonacci M; Filosa G; Giacchetti A; Ricotti G; Brandozzi G; Cataldi I; Serresi S; Ceschini R; Bugatti L; Offidani A; Giangiacomi M; Brancorsini D; Leoni P
Haematologica; 1999 Sep; 84(9):809-13. PubMed ID: 10477454
[TBL] [Abstract][Full Text] [Related]
2. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
3. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides.
Rupoli S; Goteri G; Pulini S; Filosa A; Tassetti A; Offidani M; Filosa G; Mozzicafreddo G; Giacchetti A; Brandozzi G; Cataldi I; Barulli S; Ranaldi R; Scortechini AR; Capretti R; Fabris G; Leoni P;
Eur J Haematol; 2005 Aug; 75(2):136-45. PubMed ID: 16000130
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
5. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
6. PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series.
Nikolaou V; Siakantaris MP; Vassilakopoulos TP; Papadavid E; Stratigos A; Economidi A; Marinos L; Papadaki T; Antoniou C
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):354-7. PubMed ID: 20586838
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial.
Vieyra-Garcia P; Fink-Puches R; Porkert S; Lang R; Pöchlauer S; Ratzinger G; Tanew A; Selhofer S; Paul-Gunther S; Hofer A; Gruber-Wackernagel A; Legat F; Patra V; Quehenberger F; Cerroni L; Clark R; Wolf P
JAMA Dermatol; 2019 May; 155(5):538-547. PubMed ID: 30892603
[TBL] [Abstract][Full Text] [Related]
8. [Interferon-alpha and PUVA therapy for mycosis fungoides].
Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.
Ponte P; Serrão V; Apetato M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):716-21. PubMed ID: 19929938
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
[TBL] [Abstract][Full Text] [Related]
12. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
Wozniak MB; Tracey L; Ortiz-Romero PL; Montes S; Alvarez M; Fraga J; Fernández Herrera J; Vidal S; Rodriguez-Peralto JL; Piris MA; Villuendas Deceased R
Br J Dermatol; 2009 Jan; 160(1):92-102. PubMed ID: 18945306
[TBL] [Abstract][Full Text] [Related]
13. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
14. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
15. Serum and tissue CTACK/CCL27 chemokine levels in early mycosis fungoides may be correlated with disease-free survival following treatment with interferon alfa and psoralen plus ultraviolet A therapy.
Goteri G; Rupoli S; Campanati A; Zizzi A; Picardi P; Cardelli M; Giantomassi F; Canafoglia L; Marchegiani F; Mozzicafreddo G; Brandozzi G; Stramazzotti D; Ganzetti G; Lisa R; Simonetti O; Offidani A; Federici I; Filosa G; Leoni P
Br J Dermatol; 2012 May; 166(5):948-52. PubMed ID: 22233400
[TBL] [Abstract][Full Text] [Related]
16. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands.
Hernández Z; Peñate Y; Hernández-Machín B; Pérez-Méndez L; Suárez-Hernández J; Hernández J; Fernández-de-Misa R
Int J Dermatol; 2014 Nov; 53(11):1417-22. PubMed ID: 24697305
[TBL] [Abstract][Full Text] [Related]
17. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
18. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides).
Quirós PA; Jones GW; Kacinski BM; Braverman IM; Heald PW; Edelson RL; Wilson LD
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):1027-35. PubMed ID: 9276369
[TBL] [Abstract][Full Text] [Related]
19. A chart review of patients with early stage mycosis fungoides treated with psoralen plus UVA (PUVA).
Soung J; Muigai W; Amin N; Stern DK; Lebwohl MG
J Drugs Dermatol; 2005; 4(3):290-4. PubMed ID: 15898283
[TBL] [Abstract][Full Text] [Related]
20. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]